Serotonin syndrome caused by escitalopram in Parkinson's disease psychosis: a case report.
Case report
Escitalopram
Parkinson’s disease psychosis
Serotonin syndrome
Journal
BMC geriatrics
ISSN: 1471-2318
Titre abrégé: BMC Geriatr
Pays: England
ID NLM: 100968548
Informations de publication
Date de publication:
18 Sep 2024
18 Sep 2024
Historique:
received:
14
01
2024
accepted:
09
09
2024
medline:
19
9
2024
pubmed:
19
9
2024
entrez:
18
9
2024
Statut:
epublish
Résumé
Serotonin syndrome and Parkinson's disease (PD) are two diseases whose symptoms partially overlap; this poses challenges in distinguishing them in clinical practice. Early manifestations such as tremor, akathisia, diaphoresis, hypertonia and hyperreflexia are common in mild-to-moderate serotonin syndrome and can also occur in PD. Without prompt recognition and treatment, serotonin syndrome can rapidly progress, potentially leading to severe complications such as multiple organ failure within hours. Given their disparate treatment strategies, accurate clinical distinction is crucial for effective treatment. This case study explores a patient with serotonin syndrome triggered by escitalopram in the context of PD psychosis (PDP), providing insights into diagnosis and treatment planning. A 75-year-old Asian woman with a one-year history of PD, a two-month history of PDP, and a six-year history of depression presented with symptoms including hyperreflexia, tremor, hypertonia, impaired level of consciousness, and inappropriate behavior following a recent one-month adjustment in medication. Initially suspected of being drug-induced parkinsonism or worsening PD, therapeutic drug monitoring revealed warning levels of escitalopram. Subsequent diagnoses confirmed serotonin syndrome. This syndrome may result from increased cortical serotonin activity at the serotonin2A receptor due to dopamine and serotonin imbalances in PDP, compounded by increased dopamine-mediated serotonin release. Additionally, being an intermediate metabolizer of cytochrome P450 enzyme 2C19, the patient experienced excessive escitalopram accumulation, exacerbating her condition. This case underscores the critical need to differentiate between symptoms of serotonin syndrome and PD, particularly in manifestations like tremor and hypertonia. Careful consideration of receptor profiles in patients with PDP is essential when selecting antidepressants to mitigate the risk of serotonin syndrome.
Sections du résumé
BACKGROUND
BACKGROUND
Serotonin syndrome and Parkinson's disease (PD) are two diseases whose symptoms partially overlap; this poses challenges in distinguishing them in clinical practice. Early manifestations such as tremor, akathisia, diaphoresis, hypertonia and hyperreflexia are common in mild-to-moderate serotonin syndrome and can also occur in PD. Without prompt recognition and treatment, serotonin syndrome can rapidly progress, potentially leading to severe complications such as multiple organ failure within hours. Given their disparate treatment strategies, accurate clinical distinction is crucial for effective treatment. This case study explores a patient with serotonin syndrome triggered by escitalopram in the context of PD psychosis (PDP), providing insights into diagnosis and treatment planning.
CASE PRESENTATION
METHODS
A 75-year-old Asian woman with a one-year history of PD, a two-month history of PDP, and a six-year history of depression presented with symptoms including hyperreflexia, tremor, hypertonia, impaired level of consciousness, and inappropriate behavior following a recent one-month adjustment in medication. Initially suspected of being drug-induced parkinsonism or worsening PD, therapeutic drug monitoring revealed warning levels of escitalopram. Subsequent diagnoses confirmed serotonin syndrome. This syndrome may result from increased cortical serotonin activity at the serotonin2A receptor due to dopamine and serotonin imbalances in PDP, compounded by increased dopamine-mediated serotonin release. Additionally, being an intermediate metabolizer of cytochrome P450 enzyme 2C19, the patient experienced excessive escitalopram accumulation, exacerbating her condition.
CONCLUSIONS
CONCLUSIONS
This case underscores the critical need to differentiate between symptoms of serotonin syndrome and PD, particularly in manifestations like tremor and hypertonia. Careful consideration of receptor profiles in patients with PDP is essential when selecting antidepressants to mitigate the risk of serotonin syndrome.
Identifiants
pubmed: 39294572
doi: 10.1186/s12877-024-05371-w
pii: 10.1186/s12877-024-05371-w
doi:
Substances chimiques
Escitalopram
4O4S742ANY
Selective Serotonin Reuptake Inhibitors
0
Citalopram
0DHU5B8D6V
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
769Subventions
Organisme : Jiangsu Hengrui Medicine
ID : No. H202139
Informations de copyright
© 2024. The Author(s).
Références
Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112–20.
doi: 10.1056/NEJMra041867
pubmed: 15784664
Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635–42.
doi: 10.1093/qjmed/hcg109
pubmed: 12925718
Ye H, Robak LA, Yu M, Cykowski M, Shulman JM. Genetics and pathogenesis of Parkinson’s syndrome. Annu Rev Pathol. 2023;18:95–121.
doi: 10.1146/annurev-pathmechdis-031521-034145
pubmed: 36100231
Wang RZ, Vashistha V, Kaur S, Houchens NW. Serotonin syndrome: preventing, recognizing, and treating it. Clevel Clin J Med. 2016;83(11):810–7.
doi: 10.3949/ccjm.83a.15129
Mikkelsen N, Damkier P, Pedersen SA. Serotonin syndrome-A focused review. Basic Clin Pharmacol Toxicol. 2023;133(2):124–9.
doi: 10.1111/bcpt.13912
pubmed: 37309284
Gillman PK. The serotonin syndrome and its treatment. J Psychopharmacol. 1999;13(1):100–9.
doi: 10.1177/026988119901300111
pubmed: 10221364
Abdo WF, van de Warrenburg BP, Burn DJ, Quinn NP, Bloem BR. The clinical approach to movement disorders. Nat Rev Neurol. 2010;6(1):29–37.
doi: 10.1038/nrneurol.2009.196
pubmed: 20057497
Helmich RC, Hallett M, Deuschl G, Toni I, Bloem BR. Cerebral causes and consequences of parkinsonian resting tremor: a tale of two circuits? Brain. 2012;135(Pt 11):3206–26.
doi: 10.1093/brain/aws023
pubmed: 22382359
pmcid: 3501966
Buckley NA, Dawson AH, Isbister GK. Serotonin syndrome. BMJ. 2014;348:g1626.
doi: 10.1136/bmj.g1626
pubmed: 24554467
Evans SH, Cameron MW, Burton JM. Hypertonia. Curr Probl Pediatr Adolesc Health Care. 2017;47(7):161–6.
pubmed: 28716516
Monte A, Magris R, Nardello F, Bombieri F, Zamparo P. Muscle shape changes in Parkinson’s disease impair function during rapid contractions. Acta Physiol (Oxf). 2023;238(1):e13957.
doi: 10.1111/apha.13957
pubmed: 36876976
Leodori G, Belvisi D, De Bartolo MI, Fabbrini A, Costanzo M, Vial F, Conte A, Hallett M, Berardelli A. Re-emergent Tremor in Parkinson’s disease: the role of the motor cortex. Mov Disord. 2020;35(6):1002–11.
doi: 10.1002/mds.28022
pubmed: 32175656
pmcid: 8448579
Jankovic J, Schwartz KS, Ondo W. Re-emergent tremor of Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1999;67(5):646–50.
doi: 10.1136/jnnp.67.5.646
pubmed: 10519872
pmcid: 1736624
Bhatia KP, Bain P, Bajaj N, Elble RJ, Hallett M, Louis ED, Raethjen J, Stamelou M, Testa CM, Deuschl G. Consensus Statement on the classification of tremors. from the task force on tremor of the International Parkinson and Movement Disorder Society. Mov Disord. 2018;33(1):75–87.
doi: 10.1002/mds.27121
pubmed: 29193359
Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am. 1993;77(1):185–202.
doi: 10.1016/S0025-7125(16)30278-4
pubmed: 8093494
Friedman JH. Movement disorders induced by psychiatric drugs that do not block dopamine receptors. Parkinsonism Relat Disord. 2020;79:60–4.
doi: 10.1016/j.parkreldis.2020.08.031
pubmed: 32871538
Arbaizar B, Gómez-Acebo I, Llorca J. Postural induced-tremor in psychiatry. Psychiatry Clin Neurosci. 2008;62(6):638–45.
doi: 10.1111/j.1440-1819.2008.01877.x
pubmed: 19067999
Sanger TD, Delgado MR, Gaebler-Spira D, Hallett M, Mink JW. Classification and definition of disorders causing hypertonia in childhood. Pediatrics. 2003;111(1):e89-97.
doi: 10.1542/peds.111.1.e89
pubmed: 12509602
Wieters F, Weiss Lucas C, Gruhn M, Büschges A, Fink GR, Aswendt M. Introduction to spasticity and related mouse models. Exp Neurol. 2021;335:113491.
doi: 10.1016/j.expneurol.2020.113491
pubmed: 33007294
Sheean G. The pathophysiology of spasticity. Eur J Neurol. 2002;9 Suppl 1:3–9. dicussion 53-61.
doi: 10.1046/j.1468-1331.2002.0090s1003.x
pubmed: 11918643
Gracies JM, Bayle N, Vinti M, Alkandari S, Vu P, Loche CM, Colas C. Five-step clinical assessment in spastic paresis. Eur J Phys Rehabil Med. 2010;46(3):411–21.
pubmed: 20927007
Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. JAMA. 2020;323(6):548–60.
doi: 10.1001/jama.2019.22360
pubmed: 32044947
Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic malignant syndrome. Br J Anaesth. 2000;85(1):129–35.
doi: 10.1093/bja/85.1.129
pubmed: 10928001
Prakash S. A diagnostic confusion between Serotonin syndrome and Neuroleptic malignant syndrome. Am J Emerg Med. 2021;43:272–3.
doi: 10.1016/j.ajem.2020.06.046
pubmed: 33008703
Mizuno Y, Takubo H, Mizuta E, Kuno S. Malignant syndrome in Parkinson’s disease: concept and review of the literature. Parkinsonism Relat Disord. 2003;9(Suppl 1):S3-9.
doi: 10.1016/S1353-8020(02)00125-6
pubmed: 12735909
Yamawaki Y, Ogawa N. Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) and disseminated intravascular coagulation (DIC) in a patient with Parkinson’s disease. Intern Med. 1992;31(11):1298–302.
doi: 10.2169/internalmedicine.31.1298
pubmed: 1295627
Wu J, Yu J, Qu K, Yin J, Zhu C, Liu X. Serotonin syndrome caused by a CYP2C19-mediated interaction between low-dose escitalopram and clopidogrel: a case report. Front Psych. 2023;14:1257984.
doi: 10.3389/fpsyt.2023.1257984
Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, Dhall R, Ballard C. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533–40.
doi: 10.1016/S0140-6736(13)62106-6
pubmed: 24183563
Huot P, Johnston TH, Darr T, Hazrati LN, Visanji NP, Pires D, Brotchie JM, Fox SH. Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations. Mov Disord. 2010;25(10):1399–408.
doi: 10.1002/mds.23083
pubmed: 20629135
Stahl SM. Parkinson’s disease psychosis as a serotonin-dopamine imbalance syndrome. CNS Spectr. 2016;21(5):355–9.
doi: 10.1017/S1092852916000602
pubmed: 27686027
Everett GM, Borcherding JW. L-dopa: effect on concentrations of dopamine, norepinephrine, and serotonin in brains of mice. Science. 1970;168(3933):849–50.
doi: 10.1126/science.168.3933.849
pubmed: 17768920